Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease, renal, and metabolism medicines under the CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL brand names; oncology medicines under the TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

Revenue projections:

Revenue projections for ASTRAZEN
Revenue projections for ASTRAZEN



Financial Ratios:

currentRatio 0.00000
forwardPE 0.00000
debtToEquity 2.52000
earningsGrowth 0.95300
revenueGrowth 0.44000
grossMargins 0.42979
operatingMargins 0.15426
trailingEps 38.74000
forwardEps 0.00000

ASTRAZEN's positive earnings and revenue growth suggest that the company is poised for business expansion. This financial strength indicates that ASTRAZEN is expected to continue growing, with rising profits and sales contributing to its long-term success.